SE1146865T3 - - Google Patents

Info

Publication number
SE1146865T3
SE1146865T3 SE99902781T SE99902781T SE1146865T3 SE 1146865 T3 SE1146865 T3 SE 1146865T3 SE 99902781 T SE99902781 T SE 99902781T SE 99902781 T SE99902781 T SE 99902781T SE 1146865 T3 SE1146865 T3 SE 1146865T3
Authority
SE
Sweden
Prior art keywords
sotalol
antiarrhythmic
laevo
dextro
ratio
Prior art date
Application number
SE99902781T
Other languages
English (en)
Other versions
SE1146865T5 (de
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of SE1146865T3 publication Critical patent/SE1146865T3/xx
Publication of SE1146865T5 publication Critical patent/SE1146865T5/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE99902781T 1999-02-05 1999-02-22 SE1146865T5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN89KO1999 IN188162B (de) 1999-02-05 1999-02-05

Publications (2)

Publication Number Publication Date
SE1146865T3 true SE1146865T3 (de) 2003-09-02
SE1146865T5 SE1146865T5 (de) 2003-11-18

Family

ID=38668683

Family Applications (1)

Application Number Title Priority Date Filing Date
SE99902781T SE1146865T5 (de) 1999-02-05 1999-02-22

Country Status (20)

Country Link
US (1) US6281246B2 (de)
EP (1) EP1146865B9 (de)
JP (1) JP2002536324A (de)
CN (1) CN1149987C (de)
AT (1) ATE241349T1 (de)
AU (1) AU761521C (de)
BR (1) BR9915951A (de)
CA (1) CA2348882C (de)
CZ (1) CZ20011807A3 (de)
DE (1) DE69908421T2 (de)
DK (1) DK1146865T3 (de)
ES (1) ES2195538T3 (de)
HK (1) HK1041206B (de)
HU (1) HU224033B1 (de)
IN (1) IN188162B (de)
PL (1) PL351143A1 (de)
PT (1) PT1146865E (de)
RU (1) RU2213560C2 (de)
SE (1) SE1146865T5 (de)
WO (1) WO2000045807A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105044A1 (en) 2004-05-20 2006-05-18 Singh Bramah N Sustained release formulations of sotalol
BRPI0712064B8 (pt) * 2006-05-18 2021-05-25 Dompe Spa derivados de (2r)-2-fenilpropanamida, uso e processo para preparação dos mesmos e composições farmacêuticas
CN102329254B (zh) * 2010-07-12 2014-02-05 上海奥博生物医药技术有限公司 一种制备n-[4-[1-羟基-2-[(1-甲基乙基)胺基]乙基]甲磺酰胺盐酸盐的方法
BE1021320B1 (fr) * 2014-08-27 2015-10-29 Hyloris Pharmaceuticals SA Composition pharmaceutique prete a l'emploi
BE1021328B1 (fr) * 2014-08-27 2015-10-30 Hyloris Pharmaceuticals SA Composition pharmaceutique prete a l'emploi
FR3050297A1 (fr) * 2016-04-13 2017-10-20 Assist Publique - Hopitaux De Paris Methode de determination de la susceptibilite d'induction d'une torsade de pointes
CN109419780B (zh) * 2017-09-04 2021-05-11 张家港市中医医院 一种盐酸索他洛尔片剂及其制备方法
CN109419779B (zh) * 2017-09-04 2021-05-25 鲁南制药集团股份有限公司 一种盐酸索他洛尔制剂
CN107982237B (zh) * 2018-01-17 2018-11-23 安宁 一种盐酸索他洛尔制剂及其制备方法
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089526A (en) * 1983-05-23 1992-02-18 Bristol-Myers Company Antiarrhythmic class III process
JPH01165569A (ja) * 1987-12-22 1989-06-29 Mitsui Toatsu Chem Inc 光学活性なソタロールの製造方法
IES61567B2 (en) * 1994-02-17 1994-11-16 Russinsky Ltd Pharmaceutical products

Also Published As

Publication number Publication date
HU224033B1 (hu) 2005-05-30
HK1041206B (zh) 2003-10-31
CA2348882A1 (en) 2000-08-10
PT1146865E (pt) 2003-08-29
DE69908421D1 (de) 2003-07-03
BR9915951A (pt) 2001-08-21
ATE241349T1 (de) 2003-06-15
EP1146865B9 (de) 2004-03-17
SE1146865T5 (de) 2003-11-18
JP2002536324A (ja) 2002-10-29
CN1149987C (zh) 2004-05-19
AU761521C (en) 2004-01-22
AU761521B2 (en) 2003-06-05
ES2195538T3 (es) 2003-12-01
US20010004643A1 (en) 2001-06-21
EP1146865B1 (de) 2003-05-28
HK1041206A1 (en) 2002-07-05
CN1328453A (zh) 2001-12-26
DE69908421T2 (de) 2004-03-18
US6281246B2 (en) 2001-08-28
PL351143A1 (en) 2003-03-24
RU2213560C2 (ru) 2003-10-10
EP1146865A1 (de) 2001-10-24
CA2348882C (en) 2004-07-13
WO2000045807A1 (en) 2000-08-10
CZ20011807A3 (cs) 2001-08-15
HUP0104175A3 (en) 2002-12-28
AU2296099A (en) 2000-08-25
DK1146865T3 (da) 2003-09-22
HUP0104175A2 (hu) 2002-04-29
IN188162B (de) 2002-08-31

Similar Documents

Publication Publication Date Title
SE1146865T3 (de)
Corne et al. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice
Zemlan et al. Activation of lordotic responding in female rats by suppression of serotonergic activity
ES8505519A1 (es) Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos.
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
BR0111207A (pt) Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
AU5090796A (en) Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
CO5271710A1 (es) Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
CA2408417A1 (en) Local anesthetic methods and kits
Leal et al. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
HUT74948A (en) Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema
NO20020731D0 (no) Kosttilskudd for å forbedre den muskul¶re energimetabolismen som innbefatter en alkanoylkarnitin og ribose
Taber et al. Antagonism of the analgesic effect of opioid and non-opioid agents by p-chlorophenylalanine (PCPA)
Gaggi et al. Effects of calcium antagonists on biogenic amines in discrete brain areas
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
Kimoto et al. Effects of [1-desamino-8-D-arginine] vasopressin and papaverine on rabbit renal pelvis
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
JPH0358328B2 (de)
KANETO et al. Morphine analgesia without development of tolerance in reserpinized mice
Ha et al. The action of diazepam in the isolated rat detrusor muscle